Xiamen, Aug 26, 2026 — China’s deputy drug regulator Lei Ping opened the 16th International Conference on Medical Device Supervision and Administration, pledging to deepen review reforms, tighten full-lifecycle quality controls, and align the sector with the nation’s 15th Five-Year Plan innovation targets as Beijing seeks to advance its high-end medical device industry.

Conference Snapshot

Attribute	Detail
Event	16th International Conference on Medical Device Supervision and Administration in China
Location	Xiamen, Fujian Province
Date	Aug 26, 2026
Key officials	Lei Ping, Deputy Commissioner, National Medical Products Administration (NMPA); Wu Bin, Vice Governor of Fujian Province
Attendees	Domestic and international regulators, international organizations, industry associations, academic institutions, medical device enterprises

Regulatory Priorities

Lei outlined the NMPA’s strategic focus across four pillars:

• Review reform — Sustained deepening of medical device evaluation and approval system reforms to accelerate market access.
• Innovation support — Full backing for high-end medical device research, development, and commercialization.
• Lifecycle oversight — Strengthened quality supervision across the entire product lifecycle.
• Global engagement — Expanded international regulatory cooperation and technical exchange.

15th Five-Year Plan Alignment

Lei signaled that the NMPA will anchor its next-phase agenda to the 15th Five-Year Plan development goals, emphasizing that high-efficiency regulation will serve as the foundation for high-level safety, industrial innovation, and high-quality sector growth. The framework aims to translate regulatory capacity into improved public health outcomes.

Bilateral and Industry Engagement

During the conference, Lei held a bilateral meeting with Sulyvong Chokinnaly, Deputy Director-General of the Lao Food and Drug Administration, and participated in roundtable discussions with domestic and international medical device enterprise representatives. The sessions focused on regulatory convergence, market access, and cross-border quality assurance cooperation.

Market Impact Analysis

The Xiamen summit underscores Beijing’s dual-track strategy for the medical device sector: accelerating innovation pathways for domestic high-end manufacturers while tightening quality guardrails through full-lifecycle oversight. Lei’s emphasis on 15th Five-Year Plan alignment suggests forthcoming regulatory reforms will prioritize breakthrough technologies—such as implantable devices, AI-enabled diagnostics, and advanced imaging systems—through streamlined approval channels.

For multinational device makers, the expanded international cooperation agenda signals potential convergence opportunities with China’s regulatory standards, though full-lifecycle oversight commitments imply intensified post-market surveillance obligations. The bilateral engagement with Lao regulators also highlights China’s ambition to export regulatory frameworks and capacity-building support to Southeast Asian markets, potentially smoothing market entry for Chinese device manufacturers in the Mekong region.

Forward-Looking Statement

Industry analysts expect the NMPA to roll out detailed 15th Five-Year Plan implementation guidelines for medical device supervision by late 2026 or early 2027, likely including dedicated fast-track pathways for breakthrough devices and enhanced digital surveillance infrastructure for post-market adverse event monitoring. The Xiamen conference’s focus on high-end innovation suggests regulatory capital will flow toward cardiovascular, neurological, and robotic surgery device segments, where China is seeking to reduce import dependence. Companies with pipeline candidates in these categories should prepare for accelerated review timelines coupled with stricter clinical evidence requirements.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/yaowen/ypjgyw/hyxx/ylqxhyxx/20260826181534121.html

Beijing, Aug 14, 2026 — China’s National Medical Products Administration (NMPA) endorsed centralized manufacturing models for hospital traditional Chinese medicine (TCM) preparations in an official reply to a National People’s Congress proposal, outlining a regulatory framework that shifts traditional formulas toward regional production hubs while tightening quality controls and streamlining filing requirements.

Policy Snapshot

Attribute	Detail
Document	Reply to Proposal No. 3936, 14th NPC 4th Session
Proposer	Deputy Fan Zhen
Issuers	NMPA; National Administration of Traditional Chinese Medicine
Key regulation	Revised Drug Administration Law Implementing Regulations (effective May 15, 2026)
Core focus	Hospital preparations; centralized production; regional formulation centers

Regulatory Streamlining

The NMPA highlighted that the revised Drug Administration Law Implementing Regulations, effective May 15, 2026, codify simplified pathways for hospital TCM preparations. Institutions using traditional preparation methods need only file with provincial regulators rather than seek full approval. Formulations with a five-year or longer clinical use history within the same hospital are exempt from pharmacodynamics and single- and repeat-dose toxicity studies.

The agency also clarified that outsourcing preparation no longer requires a separate regulatory license; hospitals need only file with provincial authorities as the delegating party. The rules mandate that hospital legal representatives and primary executives bear full responsibility for formulation quality, and require provincial regulators to decide on inter-hospital transfer applications within five working days.

The NMPA pointed to its 2023 measures on TCM scientific supervision, which encourage hospitals to use big data, artificial intelligence, and real-world evidence to study clinical positioning, target populations, and dosage regimens for institutional preparations. The framework explicitly supports converting proven hospital formulations with distinct advantages and low adverse-event profiles into new drug candidates.

Quality Safeguards

Regulators pledged intensified inspections of preparation and use processes, with particular scrutiny on outsourced manufacturing by small TCM clinics. The NMPA urged hospitals to establish pharmacovigilance systems for adverse reaction monitoring and endorsed multi-center clinical studies through inter-hospital transfers. The framework requires full traceability of raw materials, production controls, and quality testing.

Centralized Production Push

In the most significant policy signal, the NMPA and NATCM endorsed piloting regional formulation centers to enable shared production, unified quality control, and consolidated distribution of hospital TCM preparations. The agencies said they would draw on national drug traceability system experience to explore full-process digital tracking for institutional formulations, and will summarize local pilot experiences to refine centralized manufacturing and transfer policies.

Market Impact Analysis

The endorsement of regional formulation centers marks a structural shift for China’s hospital TCM sector, which has historically relied on fragmented in-house preparation labs. Centralized production could reduce per-unit manufacturing costs and standardize quality across institutions, but may force smaller hospitals to abandon independent formulation capabilities and rely on regional hubs.

The exemption of five-year traditional formulas from toxicity studies lowers the barrier for heritage formulations to achieve regulatory status, potentially accelerating the pipeline of hospital-developed drugs toward new drug conversion—a pathway the NMPA explicitly supports. For pharmaceutical contract manufacturers, the regional hub model creates new partnership opportunities with hospital networks, particularly in provinces with dense TCM institution clusters.

Forward-Looking Statement

Industry analysts expect the NMPA to release detailed regional formulation center guidelines within 12 to 18 months, following pilot program evaluations. The convergence of simplified filing rules, digital traceability mandates, and centralized production incentives suggests Beijing is positioning hospital TCM preparations as a controlled but strategically important bridge between traditional practice and modern pharmaceutical manufacturing. Companies with expertise in TCM formulation technology and pharmaceutical logistics are likely to benefit as provincial governments begin tendering regional hub contracts in late 2026 and 2027.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/zwgk/jyta/rdjy/20260825155646136.html